NeutralLOW severityHealthcare & Pharma6d ago

Adaptive Biotechnologies COO Julie Rubinstein sells $708,557 in stock

Adaptive Biotechnologies COO Julie Rubinstein sells $708,557 in stock — $ADPT one-month chart
$ADPT daily closes over the past month · Wook of Wall Street artwork from market data

At a glance

WOOK’s read

Adaptive Biotechnologies is near its yearly high, trading at $29.94, just below its 52-week peak of $32.13. Recent coverage has been neutral, with most mentions happening in the last week, and the Health Care sector shows calm today. The stock was sold by the COO just after the market closed.

Written by Wook AI Nov 12, 2:33 AM ET from this page’s own figures at that time — not from the article — with every number checked against them. Not investment advice.

WOOKAI ASSISTANTREADY
WOOK AIASK ANYTHING · NEVER ADVISES

Ask about ADPT. Get explanations, comparisons and calculations with the source lookups shown.

Risk check · adaptive biotechnologiesEvent risk Low

Nothing reported about adaptive biotechnologies across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.

From here · last month’s volatility 60% a year
Now $27.78Week $25.43–$30.13 (±8.5%)Month $22.96–$32.60 (±17.4%)
Ask Wook AI

Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.

Wook analysis

What it means

Key points
  • What to watch: Julie Rubinstein’s $708,557 stock sale is a clear signal — but only if you know what to look for in the numbers.
  • How the stock is trading: $ADPT -0.32% in the latest session.
  • Timing: It was published overnight, so the session change shown belongs to a day that had already closed. Market holidays are not detected.
Amount$708,557

Where the stock stands

Adaptive Biotechnologies Corpor ($ADPT) edged down 0.32% to $27.78 in the latest session. Over the past month it is up 16.0%. It now sits 14% under the 52-week high of $32.21 and 132% above the year's low of $12.00. The year's high was 2.7 times its low, which makes double-digit swings fairly routine here.

What the filings say

In its latest report (10-Q, filed Nov 4, 2026), $ADPT earned $2.9M over the quarter to Sep 30, 2026 on revenue of $83.9M (+17.3% QoQ). Operations used $6.3M of cash over the nine months to Sep 30, 2026 — about $706K a month — against $75.6M in cash on Sep 30, 2026. At that pace the cash covers about 8.9 years. Its most recent filings before this story: 10-Q on Nov 4, 2026, 8-K on Nov 4, 2026, 10-Q on Aug 4, 2026. Figures are as filed with the SEC; the $ADPT page has the full statements.

How much coverage it is getting

Wook has filed 4 stories on Adaptive Biotechnologies Corpor in the last 30 days, 2 of them this week. That is well above its usual pace: over the month it has averaged about 1 a week. Going by their wording, 0 read bullish, 4 neutral and 0 bearish. This one reads neutral too, in line with most of them. Investing.com wrote 4 of the 4 (100%), so the count reflects one outlet's output more than broad attention.

The bigger picture

In healthcare, timing is everything. A single trial result or FDA decision can shift a drugmaker’s fate, while broader policy changes ripple across the sector. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.

What to watch next

The $ADPT page has the full chart, filings, and valuation model. Compare one outlet with another to see if the story is confirmed or just repeated. Wook AI can pull live data and run the numbers on request.

Discussion

No one has weighed in yet. Start the discussion on this story.

What happened after this published

Investing.com published this on November 11, 2026. $ADPT has moved -6.93% ($29.85 to $27.78). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.

Headline and link are attributed to Investing.com. Wook of Wall Street is an independent research tool and is not affiliated with Investing.com. Nothing here is financial advice or a recommendation — research and educational content only.

Choose what Wook may measure. Essential sign-in and security cookies stay on.

Read the privacy policy